Minute Insight: Bioventus Completes Cartiheal Acquisition Following Agili-C Approval

Bioventus exercised a “call option” to acquire Cartiheal for about $315m, plus up to $135m in milestones. The US FDA recently approved Cartiheal’s Agili-C implant to treat knee joint surface lesions.